TQB-3909

N/A

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameTQB-3909
Drug Alias NameTQB-3909
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsMetastatic breast cancerPrimary MyelofibrosisMyeloproliferative Disorders +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMyeloproliferative DisordersBone Marrow NeoplasmsHematologic Neoplasms +[6] 
Inactive IndicationsMetastatic breast cancerPrimary MyelofibrosisLymphoma, Mantle-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A